Found: 37
Select item for more details and to access through your institution.
Lymph node core biopsies reliably permit diagnosis of lymphoproliferative diseases. Real‐World Experience from 554 sequential core biopsies from a single centre.
- Published in:
- European Journal of Haematology, 2021, v. 106, n. 2, p. 267, doi. 10.1111/ejh.13545
- By:
- Publication type:
- Article
WATCHFUL WAITING IN ASYMPTOMATIC ADVANCED STAGE LOW-GRADE NON-HODGKIN'S LYMPHOMA.
- Published in:
- Current Medical Literature: Leukemia & Lymphoma, 2004, v. 12, n. 2, p. 25
- By:
- Publication type:
- Article
Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 - 100 x 10<sup>9</sup>/L): Final Analysis of an Open-Label Phase 2 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 5, p. 336, doi. 10.1016/j.clml.2021.10.016
- By:
- Publication type:
- Article
ABCL-022: LOTIS-2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine (Lonca) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S377, doi. 10.1016/S2152-2650(21)01861-9
- By:
- Publication type:
- Article
Poster: ABCL-022: LOTIS-2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine (Lonca) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S238, doi. 10.1016/S2152-2650(21)01495-6
- By:
- Publication type:
- Article
Oral Abstract: ABCL-022: LOTIS-2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine (Lonca) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S203, doi. 10.1016/S2152-2650(21)01278-7
- By:
- Publication type:
- Article
Neurolymphomatosis in a patient with lymphoblastic lymphoma.
- Published in:
- British Journal of Haematology, 2012, v. 156, n. 6, p. 691, doi. 10.1111/j.1365-2141.2011.09002.x
- By:
- Publication type:
- Article
Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP chemotherapy and who respond to salvage chemotherapy.
- Published in:
- British Journal of Haematology, 2012, v. 156, n. 1, p. 142, doi. 10.1111/j.1365-2141.2011.08818.x
- By:
- Publication type:
- Article
Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%.
- Published in:
- British Journal of Haematology, 2011, v. 152, n. 2, p. 175, doi. 10.1111/j.1365-2141.2010.08447.x
- By:
- Publication type:
- Article
Cardiac tamponade in Hodgkin lymphoma.
- Published in:
- 2007
- By:
- Publication type:
- Other
Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens.
- Published in:
- British Journal of Haematology, 2005, v. 130, n. 3, p. 363, doi. 10.1111/j.1365-2141.2005.05603.x
- By:
- Publication type:
- Article
Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects.
- Published in:
- British Journal of Haematology, 2004, v. 125, n. 6, p. 756, doi. 10.1111/j.1365-2141.2004.04981.x
- By:
- Publication type:
- Article
The upregulation of CC chemokine receptor 7 and the increased migration of maturing dendritic cells to macrophage inflammatory protein 3β and secondary lymphoid chemokine is mediated by the p38 stress-activated protein kinase pathway.
- Published in:
- British Journal of Haematology, 2002, v. 119, n. 3, p. 826, doi. 10.1046/j.1365-2141.2002.03869.x
- By:
- Publication type:
- Article
Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy following anti‐CD19 CAR‐T therapy: a case report.
- Published in:
- EJHaem, 2021, v. 2, n. 4, p. 848, doi. 10.1002/jha2.274
- By:
- Publication type:
- Article
Favourable outcomes for high-risk Burkitt lymphoma patients (IPI 3-5) treated with rituximab plus CODOX-M/IVAC: Results of a phase 2 UK NCRI trial.
- Published in:
- EJHaem, 2020, v. 1, n. 1, p. 1, doi. 10.1002/jha2.3
- By:
- Publication type:
- Article
Humoral and cellular responses to SARS‐CoV‐2 in patients with B‐cell haematological malignancies improve with successive vaccination.
- Published in:
- British Journal of Haematology, 2023, v. 202, n. 6, p. 1091, doi. 10.1111/bjh.18962
- By:
- Publication type:
- Article
Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID‐19 with B‐cell malignancies.
- Published in:
- British Journal of Haematology, 2021, v. 195, n. 5, p. 706, doi. 10.1111/bjh.17836
- By:
- Publication type:
- Article
Prognostic indices in diffuse large B‐cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R‐CHOP 14 versus 21 phase 3 trial.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 6, p. 1015, doi. 10.1111/bjh.16691
- By:
- Publication type:
- Article
The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single‐centre series.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 3, p. e84, doi. 10.1111/bjh.17274
- By:
- Publication type:
- Article
FDG‐PET/CT after two cycles of R‐CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome – final result of a UK National Cancer Research Institute prospective study.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 3, p. 504, doi. 10.1111/bjh.16875
- By:
- Publication type:
- Article
Response to 'Impact of immunosuppression on mortality in critically ill COVID‐19 patients'.
- Published in:
- British Journal of Haematology, 2020, v. 191, n. 3, p. 505, doi. 10.1111/bjh.17110
- By:
- Publication type:
- Article
Clinical outcomes and risk factors for severe COVID‐19 in patients with haematological disorders receiving chemo‐ or immunotherapy.
- Published in:
- British Journal of Haematology, 2020, v. 191, n. 2, p. 194, doi. 10.1111/bjh.17027
- By:
- Publication type:
- Article
Clinical outcomes and survival of patients with myeloma and lymphoma enrolled into phase I clinical trials.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 2, p. 344, doi. 10.1111/bjh.15457
- By:
- Publication type:
- Article
Ofatumumab is a feasible alternative anti‐CD20 therapy in patients intolerant of rituximab.
- Published in:
- British Journal of Haematology, 2019, v. 184, n. 3, p. 462, doi. 10.1111/bjh.15110
- By:
- Publication type:
- Article
Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma.
- Published in:
- British Journal of Haematology, 2018, v. 181, n. 4, p. 555, doi. 10.1111/bjh.14665
- By:
- Publication type:
- Article
Cerebrospinal fluid leak after bone marrow biopsy.
- Published in:
- 2018
- By:
- Publication type:
- Case Study
Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting.
- Published in:
- British Journal of Haematology, 2017, v. 179, n. 3, p. 471, doi. 10.1111/bjh.14898
- By:
- Publication type:
- Article
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R- CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R- CHOP 14 versus 21 trial.
- Published in:
- British Journal of Haematology, 2016, v. 175, n. 4, p. 668, doi. 10.1111/bjh.14287
- By:
- Publication type:
- Article
Autologous stem cell transplantation outcomes in elderly patients with B cell Non-Hodgkin Lymphoma.
- Published in:
- British Journal of Haematology, 2015, v. 171, n. 2, p. 197, doi. 10.1111/bjh.13561
- By:
- Publication type:
- Article
Central nervous system prophylaxis in patients with diffuse large B cell lymphoma, are we treating ourselves? A response to the recent BCSH Guideline - response to Griffin et al.
- Published in:
- British Journal of Haematology, 2014, v. 167, n. 4, p. 579, doi. 10.1111/bjh.13017
- By:
- Publication type:
- Article
Central nervous system prophylaxis in patients with diffuse large B cell lymphoma (DLBCL), are we treating ourselves? A response to the recent British Committee for Standards in Haematology (BCSH) Guideline – response to Griffin et al.
- Published in:
- British Journal of Haematology, 2014, v. 166, n. 1, p. 1, doi. 10.1111/bjh.13017
- By:
- Publication type:
- Article
Guidelines for the first line management of classical Hodgkin lymphoma.
- Published in:
- British Journal of Haematology, 2014, v. 166, n. 1, p. 34, doi. 10.1111/bjh.12878
- By:
- Publication type:
- Article
Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure.
- Published in:
- British Journal of Haematology, 2014, v. 165, n. 3, p. 334, doi. 10.1111/bjh.12741
- By:
- Publication type:
- Article
Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology.
- Published in:
- British Journal of Haematology, 2013, v. 163, n. 2, p. 168, doi. 10.1111/bjh.12509
- By:
- Publication type:
- Article
Whole Body 3.0 T Magnetic Resonance Imaging in Lymphomas: Comparison of Different Sequence Combinations for Staging Hodgkin's and Diffuse Large B Cell Lymphomas.
- Published in:
- Journal of Personalized Medicine, 2020, v. 10, n. 4, p. 284, doi. 10.3390/jpm10040284
- By:
- Publication type:
- Article
Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study.
- Published in:
- 2021
- By:
- Publication type:
- journal article
R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article